Ignite Creation Date:
2025-12-24 @ 5:05 PM
Ignite Modification Date:
2026-01-28 @ 2:02 PM
Study NCT ID:
NCT05325450
Status:
UNKNOWN
Last Update Posted:
2023-08-24
First Post:
2022-03-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Optimization of Hearing Performance in the Subject Implanted
Sponsor:
University Hospital, Toulouse
Organization:
Study Overview
Official Title:
Optimization of Hearing Performance in the Subject Implanted With Profound Asymmetric Deafness
Status:
UNKNOWN
Status Verified Date:
2023-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPERSA
Brief Summary:
In the past two decades, the selection criteria for cochlear implantation have been greatly relaxed so that about 60-70% of present cochlear implant (CI) candidates have significant residual hearing in their contralateral ear. However, contralateral hearing is often not considered in rehabilitation programs, mainly due to the lack of scientific evidence on the role it may play. The present project aims to better understand the mechanisms of perceptual learning of CI-processed speech after implantation and to develop and test rehabilitation strategies for CI users.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: